| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R03DX05 | BioTech | Omalizumab - 150mg | 10817 | 163820/1 | XOLAIR | 150mg | 1 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | 30,766,872 L.L | 19.35 | D | Novartis Europharm Limited | Ireland | 3/11/202 |
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R03DX05 | BioTech | Omalizumab - 150mg | 10817/388 | 163820/1 | XOLAIR | 150mg | 1 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | L.L | 19.35 | D | Novartis Europharm Limited | Ireland | 3/11/202 |
